ELDN Eledon Pharmaceuticals Inc
6,292
$2.40
$0.04
(1.64%)
| Watchers | 6,292 |
| 52-Wk Low | $1.07 |
| 52-Wk High | $2.80 |
| Market Cap | $58.08M |
| Volume | 171,171.00 |
| 52-Wk High | $2.80 |
| 52-Wk Low | $1.07 |
Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased ConfidenceBenzinga • 3 days ago
Eledon Pharmaceuticals' results from islet cell transplant trial for type 1 diabetes, with tegoprubart showing safety and efficacy in kidney transplant patients. Analysts anticipate significant...
Share to Feed
Eledon Pharmaceuticals, Inc. (ELDN) has disclosed a new risk, in the Share Price & Shareholder Rights category. Eledon Pharmaceuticals, Inc. faces...
In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Eledon Pharmaceuticals (ELDN Research Report), with a p...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection Tegoprubart used as a component of the immunosuppressive treatment regimen following...
IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ( Eledon ) (NASDAQ: ELDN) today announced the enrollment of the 12th participant on March 23, 2024, in the Company's...
Eledon Pharmaceuticals (NASDAQ:ELDN Get Free Report)s stock had its buy rating reissued by analysts at HC Wainwright in a note issued to investors on Friday, Benzinga...
Historic kidney xenotransplantation procedure conducted at Massachusetts General Hospital Tegoprubart administration has now been used investigationally to prevent rejection in both kidney and heart...
Armistice Capital LLC decreased its position in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN Free Report) by 1.0% during the 3rd quarter, according to the company in its most recent...
IRVINE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ( Eledon ) (NASDAQ: ELDN) today announced that the Company's Compensation Committee granted 42,500 restricted stock...